Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Symmans WF, et al. Among authors: moulder s. J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135148 Free PMC article.
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. Sparano JA, et al. Among authors: moulder s. J Clin Oncol. 2006 Jul 1;24(19):3013-8. doi: 10.1200/JCO.2005.04.9114. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769985 Clinical Trial.
Adjuvant biologic therapy for breast cancer.
Craft BS, Hortobagyi GN, Moulder SL. Craft BS, et al. Among authors: moulder sl. Cancer J. 2007 May-Jun;13(3):156-61. doi: 10.1097/PPO.0b013e318074d80a. Cancer J. 2007. PMID: 17620764 Review.
Advances in the treatment of breast cancer.
Moulder S, Hortobagyi GN. Moulder S, et al. Clin Pharmacol Ther. 2008 Jan;83(1):26-36. doi: 10.1038/sj.clpt.6100449. Epub 2007 Dec 19. Clin Pharmacol Ther. 2008. PMID: 18091763 Review.
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Moulder SL, et al. Clin Cancer Res. 2008 Dec 1;14(23):7909-16. doi: 10.1158/1078-0432.CCR-08-1104. Clin Cancer Res. 2008. PMID: 19047121 Free PMC article. Clinical Trial.
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Liedtke C, et al. Among authors: moulder s. Ann Oncol. 2009 Dec;20(12):1953-8. doi: 10.1093/annonc/mdp263. Epub 2009 Jul 12. Ann Oncol. 2009. PMID: 19596702 Free PMC article.
158 results